Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387610 | 0.89 | HDAC2 (0.43) | GPR119HDAC2HDAC1TACR1JAK2 | |
| SCHEMBL22266048 | 0.84 | HDAC2 (0.41) | GPR119HDAC2HDAC1TACR1JAK2 | |
| SCHEMBL7534118 | 0.84 | HDAC2 (0.43) | GPR119HDAC2HDAC1TACR1JAK2 | |
| SCHEMBL3385458 | 0.83 | MEN1 (0.43) | HDAC2HDAC1TACR1S1PR2OPRD1 | |
| SCHEMBL1010786 | 0.83 | S1PR2 (0.40) | S1PR2OPRD1OPRK1DRD2 | |
| SCHEMBL4820978 | 0.82 | GPR119 (0.46) | GPR119TACR1ALOX15TSHRATM | |
| SCHEMBL2427136 | 0.82 | RORC (0.44) | GPR119HDAC2HDAC1TACR1JAK2 | |
| SCHEMBL3266179 | 0.81 | RORC (0.51) | HDAC2HDAC1S1PR2RORCDRD2 | |
| SCHEMBL1010168 | 0.81 | GPR119 (0.48) | GPR119S1PR2 | |
| SCHEMBL4293214 | 0.80 | OPRM1 (0.49) | GPR119HDAC2HDAC1TACR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| EP-1948606-B1 | 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2011-01-05 | — | — | EP | disclosed |
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SANIONA AB (DK) | 2008-09-25 | — | — | US | disclosed |
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SANIONA AB (DK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SLC6A3, DRD2, DRD3 | GPR119 265/4885HDAC2 1278/4885HDAC1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.